S&P 500   4,283.74 (+0.23%)
DOW   33,999.04 (+0.06%)
QQQ   329.28 (+0.24%)
AAPL   174.15 (-0.23%)
MSFT   290.17 (-0.39%)
META   174.66 (-0.11%)
GOOGL   120.17 (+0.52%)
AMZN   142.30 (+0.14%)
TSLA   908.61 (-0.37%)
NVDA   187.73 (+2.39%)
NIO   19.91 (-0.85%)
BABA   90.74 (+1.08%)
AMD   100.44 (+2.21%)
T   18.43 (+0.05%)
MU   62.98 (+2.21%)
CGC   3.81 (-6.16%)
F   16.15 (+0.75%)
GE   79.21 (-0.89%)
DIS   122.67 (-0.11%)
AMC   19.29 (-9.69%)
PYPL   99.86 (+0.44%)
PFE   48.58 (-1.40%)
NFLX   245.17 (+1.67%)
S&P 500   4,283.74 (+0.23%)
DOW   33,999.04 (+0.06%)
QQQ   329.28 (+0.24%)
AAPL   174.15 (-0.23%)
MSFT   290.17 (-0.39%)
META   174.66 (-0.11%)
GOOGL   120.17 (+0.52%)
AMZN   142.30 (+0.14%)
TSLA   908.61 (-0.37%)
NVDA   187.73 (+2.39%)
NIO   19.91 (-0.85%)
BABA   90.74 (+1.08%)
AMD   100.44 (+2.21%)
T   18.43 (+0.05%)
MU   62.98 (+2.21%)
CGC   3.81 (-6.16%)
F   16.15 (+0.75%)
GE   79.21 (-0.89%)
DIS   122.67 (-0.11%)
AMC   19.29 (-9.69%)
PYPL   99.86 (+0.44%)
PFE   48.58 (-1.40%)
NFLX   245.17 (+1.67%)
S&P 500   4,283.74 (+0.23%)
DOW   33,999.04 (+0.06%)
QQQ   329.28 (+0.24%)
AAPL   174.15 (-0.23%)
MSFT   290.17 (-0.39%)
META   174.66 (-0.11%)
GOOGL   120.17 (+0.52%)
AMZN   142.30 (+0.14%)
TSLA   908.61 (-0.37%)
NVDA   187.73 (+2.39%)
NIO   19.91 (-0.85%)
BABA   90.74 (+1.08%)
AMD   100.44 (+2.21%)
T   18.43 (+0.05%)
MU   62.98 (+2.21%)
CGC   3.81 (-6.16%)
F   16.15 (+0.75%)
GE   79.21 (-0.89%)
DIS   122.67 (-0.11%)
AMC   19.29 (-9.69%)
PYPL   99.86 (+0.44%)
PFE   48.58 (-1.40%)
NFLX   245.17 (+1.67%)
S&P 500   4,283.74 (+0.23%)
DOW   33,999.04 (+0.06%)
QQQ   329.28 (+0.24%)
AAPL   174.15 (-0.23%)
MSFT   290.17 (-0.39%)
META   174.66 (-0.11%)
GOOGL   120.17 (+0.52%)
AMZN   142.30 (+0.14%)
TSLA   908.61 (-0.37%)
NVDA   187.73 (+2.39%)
NIO   19.91 (-0.85%)
BABA   90.74 (+1.08%)
AMD   100.44 (+2.21%)
T   18.43 (+0.05%)
MU   62.98 (+2.21%)
CGC   3.81 (-6.16%)
F   16.15 (+0.75%)
GE   79.21 (-0.89%)
DIS   122.67 (-0.11%)
AMC   19.29 (-9.69%)
PYPL   99.86 (+0.44%)
PFE   48.58 (-1.40%)
NFLX   245.17 (+1.67%)
NASDAQ:AVEO

AVEO Pharmaceuticals - AVEO Stock Forecast, Price & News

$7.69
-0.05 (-0.65%)
(As of 08/18/2022 12:00 AM ET)
Add
Compare
Today's Range
$7.12
$7.78
50-Day Range
$3.99
$8.01
52-Week Range
$3.06
$8.25
Volume
253,815 shs
Average Volume
285,617 shs
Market Capitalization
$266.18 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$18.00

AVEO Pharmaceuticals MarketRank™ Forecast

Analyst Rating
Buy
3.00 Rating Score
Upside/​Downside
133.8% Upside
$18.00 Price Target
Short Interest
Healthy
3.59% of Float Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
1.11mentions of AVEO Pharmaceuticals in the last 14 days
Based on 7 Articles This Week
Insider Trading
N/A
Proj. Earnings Growth
Growing
From ($0.94) to $0.41 Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.28 out of 5 stars

Medical Sector

426th out of 1,119 stocks

Pharmaceutical Preparations Industry

209th out of 549 stocks

AVEO stock logo

About AVEO Pharmaceuticals (NASDAQ:AVEO) Stock

AVEO Pharmaceuticals, Inc., a biopharmaceutical company, focuses on developing and commercializing medicines for cancer patients. It markets its lead candidate, FOTIVDA, an oral, once-daily, vascular endothelial growth factor receptor tyrosine kinase inhibitor, which is used for the treatment of renal cell carcinoma (RCC); and tivozanib for the treatment of RCC, HCC, immunologically cold tumors, and CCA. The company has also completed a Phase II clinical trial of tivozanib in combination with Opdivo (nivolumab) for the treatment of RCC. In addition, it is developing Ficlatuzumab, a potent humanized immunoglobulin G1 (IgG1) monoclonal antibody that targets hepatocyte growth factor that is in a Phase II clinical trial for the treatment of squamous cell carcinoma of the head and neck, pancreatic cancer, and acute myeloid leukemia; AV-203, a potent humanized IgG1 monoclonal antibody, which completed Phase I clinical trial for treating human ErbB3; and AV-380, a potent humanized IgG1 inhibitory monoclonal antibody that is in a Phase I clinical trial for the treatment or prevention of cachexia. The company's preclinical stage product includes AV-353 that targets the Notch 3 pathway. AVEO Pharmaceuticals, Inc. has collaboration agreements with CANbridge Life Sciences Ltd.; EUSA Pharma (UK) Limited; Novartis International Pharmaceutical Ltd.; Biodesix, Inc.; St. Vincent's Hospital Sydney Limited; Biogen Idec International GmbH; Kyowa Kirin Co., Ltd.; and AstraZeneca PLC. The company was formerly known as GenPath Pharmaceuticals, Inc. and changed its name to AVEO Pharmaceuticals, Inc. in March 2005. AVEO Pharmaceuticals, Inc. was incorporated in 2001 and is headquartered in Boston, Massachusetts.

Analyst Upgrades and Downgrades

A number of research analysts have recently commented on the company. SVB Leerink reaffirmed an "outperform" rating on shares of AVEO Pharmaceuticals in a research note on Wednesday, July 27th. StockNews.com raised shares of AVEO Pharmaceuticals from a "hold" rating to a "buy" rating in a report on Monday.

AVEO Pharmaceuticals Price Performance

AVEO traded down $0.04 on Thursday, hitting $7.70. The company had a trading volume of 3,355 shares, compared to its average volume of 233,081. The company has a quick ratio of 3.06, a current ratio of 3.10 and a debt-to-equity ratio of 1.09. AVEO Pharmaceuticals has a 1 year low of $3.06 and a 1 year high of $8.25. The company's fifty day moving average price is $6.56 and its 200 day moving average price is $5.21.

AVEO Pharmaceuticals (NASDAQ:AVEO - Get Rating) last announced its quarterly earnings results on Thursday, August 4th. The biopharmaceutical company reported ($0.24) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.28) by $0.04. AVEO Pharmaceuticals had a negative return on equity of 87.81% and a negative net margin of 45.72%. During the same quarter in the prior year, the business posted ($0.48) earnings per share. As a group, equities analysts expect that AVEO Pharmaceuticals will post -0.94 earnings per share for the current fiscal year.

Receive AVEO Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for AVEO Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

AVEO Stock News Headlines

A Current Assessment On AVEO Pharmaceuticals
AVEO Pharmaceuticals, Inc. (AVEO)
AVEO Pharmaceuticals Earnings Preview
AVEO Pharmaceuticals Is Primed For A Breakout
AVEO Pharmaceuticals Q1 2022 Earnings Preview
See More Headlines
Receive AVEO Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for AVEO Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

AVEO Company Calendar

Last Earnings
8/04/2022
Today
8/18/2022
Next Earnings (Estimated)
11/14/2022
Fiscal Year End
12/31/2022

Industry, Sector and Symbol

Industry
Pharmaceutical preparations
Sub-Industry
Biotechnology
Sector
Medical
Current Symbol
NASDAQ:AVEO
CUSIP
05358810
Employees
114
Year Founded
2001

Price Target and Rating

Average Stock Price Forecast
$18.00
High Stock Price Forecast
$18.00
Low Stock Price Forecast
$18.00
Forecasted Upside/Downside
+134.1%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
2 Analysts

Profitability

Net Income
$-53,340,000.00
Pretax Margin
-45.72%

Debt

Sales & Book Value

Annual Sales
$42.29 million
Book Value
$0.88 per share

Miscellaneous

Free Float
33,576,000
Market Cap
$266.18 million
Optionable
Optionable
Beta
0.79

Social Links


Key Executives

  • Mr. Michael P. BaileyMr. Michael P. Bailey (Age 57)
    CEO, Pres & Director
    Comp: $967.12k
  • Mr. Erick J. Lucera CFA (Age 54)
    CPA, Chief Financial Officer
    Comp: $524.21k
  • Mr. Michael FerraressoMr. Michael Ferraresso (Age 48)
    Chief Commercial Officer
    Comp: $531.55k
  • Mr. Jeb Ledell
    Chief Operating Officer
  • Dr. Emile Farhan
    Sr. VP of Technical Operations & Quality Assurance
  • Ms. Danielle Holland
    VP of Legal & Corp. Sec.
  • Mr. Kevin Peacock
    Sr. VP of Marketing
  • Mr. David Crist
    VP of Sales
  • Ms. Catherine DeRose
    VP of HR
  • Ms. Anisha Wharton
    Head of Regulatory Affairs













AVEO Stock - Frequently Asked Questions

Should I buy or sell AVEO Pharmaceuticals stock right now?

2 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for AVEO Pharmaceuticals in the last year. There are currently 2 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" AVEO shares.
View AVEO analyst ratings
or view top-rated stocks.

What is AVEO Pharmaceuticals' stock price forecast for 2022?

2 Wall Street analysts have issued twelve-month target prices for AVEO Pharmaceuticals' stock. Their AVEO share price forecasts range from $18.00 to $18.00. On average, they predict the company's stock price to reach $18.00 in the next year. This suggests a possible upside of 134.1% from the stock's current price.
View analysts price targets for AVEO
or view top-rated stocks among Wall Street analysts.

How have AVEO shares performed in 2022?

AVEO Pharmaceuticals' stock was trading at $4.69 at the beginning of 2022. Since then, AVEO stock has increased by 64.0% and is now trading at $7.69.
View the best growth stocks for 2022 here
.

When is AVEO Pharmaceuticals' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Monday, November 14th 2022.
View our AVEO earnings forecast
.

How were AVEO Pharmaceuticals' earnings last quarter?

AVEO Pharmaceuticals, Inc. (NASDAQ:AVEO) issued its quarterly earnings results on Thursday, August, 4th. The biopharmaceutical company reported ($0.24) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.28) by $0.04. AVEO Pharmaceuticals had a negative net margin of 45.72% and a negative trailing twelve-month return on equity of 87.81%. During the same period in the prior year, the company posted ($0.48) EPS.

When did AVEO Pharmaceuticals' stock split?

Shares of AVEO Pharmaceuticals reverse split on the morning of Thursday, February 20th 2020. The 1-10 reverse split was announced on Wednesday, February 19th 2020. The number of shares owned by shareholders was adjusted after the market closes on Wednesday, February 19th 2020. An investor that had 100 shares of stock prior to the reverse split would have 10 shares after the split.

What is Tuan Ha-Ngoc's approval rating as AVEO Pharmaceuticals' CEO?

4 employees have rated AVEO Pharmaceuticals Chief Executive Officer Tuan Ha-Ngoc on Glassdoor.com. Tuan Ha-Ngoc has an approval rating of 61% among the company's employees. This puts Tuan Ha-Ngoc in the bottom 25% of approval ratings compared to other CEOs of publicly-traded companies. 48.0% of employees surveyed would recommend working at AVEO Pharmaceuticals to a friend.

What other stocks do shareholders of AVEO Pharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some companies that other AVEO Pharmaceuticals investors own include Exelixis (EXEL), Micron Technology (MU), Advanced Micro Devices (AMD), Inovio Pharmaceuticals (INO), OPKO Health (OPK), Novavax (NVAX), Sorrento Therapeutics (SRNE), Corbus Pharmaceuticals (CRBP), Synergy Pharmaceuticals (SGYP) and NVIDIA (NVDA).

What is AVEO Pharmaceuticals' stock symbol?

AVEO Pharmaceuticals trades on the NASDAQ under the ticker symbol "AVEO."

Who are AVEO Pharmaceuticals' major shareholders?

AVEO Pharmaceuticals' stock is owned by a variety of institutional and retail investors. Top institutional investors include Millennium Management LLC (1.86%), Renaissance Technologies LLC (0.36%), Brandywine Global Investment Management LLC (0.32%), Northern Trust Corp (0.15%), Goldman Sachs Group Inc. (0.06%) and Group One Trading L.P. (0.00%). Insiders that own company stock include Michael Ferraresso, Michael P Bailey and Peter W Sonsini.
View institutional ownership trends
.

How do I buy shares of AVEO Pharmaceuticals?

Shares of AVEO stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is AVEO Pharmaceuticals' stock price today?

One share of AVEO stock can currently be purchased for approximately $7.69.

How much money does AVEO Pharmaceuticals make?

AVEO Pharmaceuticals (NASDAQ:AVEO) has a market capitalization of $266.18 million and generates $42.29 million in revenue each year. The biopharmaceutical company earns $-53,340,000.00 in net income (profit) each year or ($1.05) on an earnings per share basis.

How many employees does AVEO Pharmaceuticals have?

The company employs 114 workers across the globe.

When was AVEO Pharmaceuticals founded?

AVEO Pharmaceuticals was founded in 2001.

How can I contact AVEO Pharmaceuticals?

AVEO Pharmaceuticals' mailing address is 30 WINTER STREET, BOSTON MA, 02108. The official website for the company is www.aveooncology.com. The biopharmaceutical company can be reached via phone at (617) 400-0101, via email at ir@aveooncology.com, or via fax at 617-995-4995.

This page (NASDAQ:AVEO) was last updated on 8/18/2022 by MarketBeat.com Staff

MarketBeat Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau MarketBeat is rated as Great on TrustPilot

© American Consumer News, LLC dba MarketBeat® 2010-2022. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | contact@marketbeat.com | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Privacy Policy | Do Not Sell My Information | RSS Feeds

© 2022 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see Barchart's disclaimer.